Samira Beckwith - Nov 3, 2023 Form 4 Insider Report for Tabula Rasa HealthCare, Inc. (TRHC)

Role
Director
Signature
/s/ Brian W. Adams, by Power of Attorney
Stock symbol
TRHC
Transactions as of
Nov 3, 2023
Transactions value $
-$1,203
Form type
4
Date filed
11/14/2023, 06:14 PM
Previous filing
Jun 13, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRHC Common Stock Disposed to Issuer -62.7K -70.96% 25.6K Nov 3, 2023 Direct F1
transaction TRHC Common Stock Disposed to Issuer -25.6K -100% 0 Nov 3, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRHC Stock Option (Right to Buy) Disposed to Issuer -$1.2K -257 -100% $4.68 0 Nov 3, 2023 Common Stock 257 $5.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Samira Beckwith is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 62,658 shares of common stock of the Company ("Common Stock") were converted into the right to receive a cash payment of $657,909, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock owned by the reporting person, by (y) the offer price ($10.50).
F2 Upon the consummation of the Merger, pursuant to the Merger Agreement, 25,641 unvested restricted stock awards ("RSAs") were cancelled and converted into the right to receive a cash payment of $269,230.50, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock underlying the RSAs, by (y) the offer price ($10.50).
F3 Upon the consummation of the Merger, pursuant to the Merger Agreement, 257 stock options (the "Options") were cancelled and converted into the right to receive a cash payment of $1,202.76, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock underlying the Options, by (y) the amount by which the offer price ($10.50) exceeds the per share exercise price of the Options.